<--Back to project organisation page
Work package 4
Compounds from WP1, WP2, WP3 will be further analysed by groups oriented to
characterization and validation of PKs as drug targets, especially as
regards structural and functional studies. These laboratories will give the
feedback of bio-activity to the screening/synthesis laboratories (WP1, WP2,
WP3).
It is essential to get the feedback information from biological tests as
soon as possible, and therefore the bioactivity testing should be done
parallel to the synthesis work.
Synthesis of pure chemicals takes a relatively long period of time as
compared to make tests. New bioactivity tests will be developed and this
development also requires long time. These are done in parallel.
| Groups in WP 4: |
||
| University of Dundee MRC Protein Phosphorylation Unit, MSI/WTB Complex |
||
| Prof. Sir Philip Cohen |
||
| Venetian Institute for Molecular Medicine (VIMM) and University of Padova, Departments of Biological Chemistry and Organic Chemistry | ||
| Prof. Lorenzo A. Pinna | ||
| Prof. Giuseppe Zanotti |
||
| Cancer Research UK London Research Institute, Protein Phosphorylation and Structural Biology Laboratories |
||
| Prof. Peter J. Parker |
||
| University of Oxford Laboratory of Molecular Biophysics |
||
| Prof. Dame Louise N. Johnson | ||
| Dr. Jane A. Endicott | ||
| Dr. Jim McDonnell | ||
| Dr. Martin E. M. Noble |
||
| Innsbruck Medical University | ||
| Prof. Johann Hofmann |
||
| University of Milano-Bicocca | ||
| Dr. Carlo Gambacorti-Passerini Dr. Rosalind Gunby |
||
| ProQinase/KTB Tumourforschungs GmbH | ||
| Dr. Michael Kubbutat |
||
| Pepscan Systems BV | ||
| Dr. Peter van Dijken |
||
| Dr. Jos Joore | ||